EGFR and lung carcinoma: Chaib et al. reported that increased expression of STAT3 or YAP1 was associated with poor progression-free survival (PFS) in NSCLC patients harboring EGFR mutation who received first-line EGFR-TKIs, suggesting that both Src-YAP axis and STAT3 can lead to a reduced response to EGFR-TKIs in lung cancer [100].